Four products are in development for hematology and oncology indications:
- The company’s lead product, SANGUINATE™, is in clinical testing, focused on treating the comorbidities of sickle cell disease and other disorders caused by ischemia, hypoxia and/or hemolysis.
- ANF-Rho™ is the result of combining state-of-the-art protein engineering technology with advanced PEGylation techniques to create a novel molecule with a unique mechanism of action. Phase II trials are expected to begin in 4Q/2015.
- EPEG® is a long-acting 3rd generation PEGylated EPO biologic in clinical development for the treatment of anemia; a comorbidity common with chronic kidney disease and cancer chemotherapy. Phase I trials are completed. Prolong retains development and commercialization rights in US, Europe and China. Zydus-Cadila has rights in the rest of the world.
- PP-403 is a novel cytokine with broad applications in cancer.